肠道菌群
生物
候选基因
基因
黄芩
炎症性肠病
代谢组学
计算生物学
失调
疾病
人参
免疫系统
亚细胞定位
微生物学
肠道细菌
基因组
药物数据库
遗传学
双歧杆菌
模式生物
中草药
药物发现
基因组
寄主(生物学)
结肠炎
基因表达
作者
Zimo Wang,Yinghui You,Xinxia Song,Tangyu Yuan,Zhenjiang Zhang,Pengtao Liu
摘要
OBJECTIVES: Crohn's disease is a chronic inflammatory bowel disease associated with gut microbiota imbalance and immune dysregulation. This study aimed to identify candidate key protein targets of Crohn's disease and explore candidate therapeutic compounds derived from gut microbiota metabolites and medicinal plants. METHODS: Gene expression data from Crohn's disease patients were obtained from public databases. Hub targets of gut microbiota metabolites were retrieved from the gutMGene database, and NOD2-related genes were obtained from GeneCards. Differentially expressed genes were identified using machine learning combined with feature attribution analysis. Subcellular localization and external datasets were used for validation. Drug-likeness and toxicity of microbial metabolites were assessed, and active compounds from medicinal plants were predicted via database mining and validated by molecular docking. KEY FINDINGS: Interleukin-1 beta and matrix metalloproteinase-1 were identified as key genes. Seven gut microbiota-derived metabolites showed favourable drug-likeness without predicted carcinogenicity or hepatotoxicity. Several compounds from Panax ginseng and Scutellaria baicalensis exhibited strong binding affinity to the target proteins. CONCLUSIONS: Interleukin-1 beta and matrix metalloproteinase-1 are candidate key proteins in Crohn's disease and are associated with the NOD2-related downstream inflammatory network, including nuclear factor kappa-B signalling. Gut microbiota metabolites may influence this network and represent candidate molecules for further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI